Adult Growth Hormone Deficiency vs. GH Secretagogues: Two Very Different Treatment Pathways

Adult growth hormone deficiency (AGHD) is a genuine, diagnosable medical condition with an FDA-approved treatment pathway — recombinant human growth hormone (rhGH) itself, administered under specialist monitoring. This is worth clearly distinguishing from the GH secretagogues (GHRH analogs, GHRPs like ipamorelin) discussed throughout the peptide space, which work through a different approach entirely.

What AGHD Actually Is

Adult growth hormone deficiency is a specific, diagnosable endocrine condition, most commonly resulting from pituitary damage (tumors, surgery, radiation, traumatic brain injury) that impairs the pituitary's ability to produce growth hormone, confirmed through dynamic stimulation testing rather than a single blood draw, since GH is normally secreted in pulses rather than at a stable baseline level. This is a genuine medical diagnosis with real, well-characterized symptoms (reduced lean mass, increased fat mass, reduced bone density, reduced quality of life, adverse cardiovascular risk markers) — distinct from age-related decline in GH pulse amplitude that all adults experience to some degree without qualifying as a diagnosable deficiency.

The Approved Treatment: Direct rhGH Replacement

Diagnosed AGHD is treated with direct recombinant human growth hormone injections, an FDA-approved replacement therapy dosed and monitored by an endocrinologist, typically involving periodic IGF-1 level checks, bone density monitoring, and glucose metabolism monitoring given GH's known effects on insulin sensitivity. This is a fundamentally different approach from secretagogues: rhGH directly supplies the hormone itself, bypassing the pituitary's own production entirely, appropriate specifically because the diagnosis is that the pituitary can't produce adequate GH on its own.

Why Secretagogues Work Through a Different Logic

GHRH analogs and GHRPs, by contrast, work by stimulating the pituitary to produce and release more of its own GH — a mechanism that only makes physiological sense in someone whose pituitary is still capable of producing GH, which is most people using these compounds for body composition or anti-aging purposes, not people with a diagnosed pituitary-failure form of AGHD. This is a meaningful distinction: secretagogues in a healthy pituitary amplify existing capacity, while rhGH in confirmed AGHD replaces a capacity that's actually absent.

Evidence and Regulatory Status Comparison

rhGH for AGHD has the evidence and regulatory backing of a formally approved, specifically indicated drug, with dosing and monitoring protocols established through the same rigorous process behind other approved hormone replacement therapies. GH secretagogues, as discussed in the earlier comparison of ipamorelin, CJC-1295, and sermorelin, have real receptor-level mechanistic support but a comparatively thinner long-term human outcome evidence base and are not FDA-approved for general anti-aging or body-composition use, circulating mainly through research-chemical and compounding channels instead.

Practical Takeaway

Diagnosed adult growth hormone deficiency and the general population interest in GH secretagogues represent two genuinely different situations: a specific medical diagnosis treated with approved, directly-replacing rhGH under specialist monitoring, versus a self-directed use of pituitary-stimulating peptides in people whose GH production is intact but who want to amplify it. Confusing the strong evidence base behind AGHD treatment with the thinner evidence base behind secretagogue use in healthy adults is a common but meaningful category error worth avoiding.